HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Abstract
Hepatocellular carcinomas represent the third leading cause of cancer-related deaths worldwide. The vast majority of cases arise in the context of chronic liver injury due to hepatitis B virus or hepatitis C virus infection. To identify genetic mechanisms of hepatocarcinogenesis, we characterized copy number alterations and gene expression profiles from the same set of tumors associated with hepatitis C virus. Most tumors harbored 1q gain, 8q gain, or 8p loss, with occasional alterations in 13 additional chromosome arms. In addition to amplifications at 11q13 in 6 of 103 tumors, 4 tumors harbored focal gains at 6p21 incorporating vascular endothelial growth factor A (VEGFA). Fluorescence in situ hybridization on an independent validation set of 210 tumors found 6p21 high-level gains in 14 tumors, as well as 2 tumors with 6p21 amplifications. Strikingly, this locus overlapped with copy gains in 4 of 371 lung adenocarcinomas. Overexpression of VEGFA via 6p21 gain in hepatocellular carcinomas suggested a novel, non-cell-autonomous mechanism of oncogene activation. Hierarchical clustering of gene expression among 91 of these tumors identified five classes, including "CTNNB1", "proliferation", "IFN-related", a novel class defined by polysomy of chromosome 7, and an unannotated class. These class labels were further supported by molecular data; mutations in CTNNB1 were enriched in the "CTNNB1" class, whereas insulin-like growth factor I receptor and RPS6 phosphorylation were enriched in the "proliferation" class. The enrichment of signaling pathway alterations in gene expression classes provides insights on hepatocellular carcinoma pathogenesis. Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic therapies.
AuthorsDerek Y Chiang, Augusto Villanueva, Yujin Hoshida, Judit Peix, Philippa Newell, Beatriz Minguez, Amanda C LeBlanc, Diana J Donovan, Swan N Thung, Manel Solé, Victoria Tovar, Clara Alsinet, Alex H Ramos, Jordi Barretina, Sasan Roayaie, Myron Schwartz, Samuel Waxman, Jordi Bruix, Vincenzo Mazzaferro, Azra H Ligon, Vesna Najfeld, Scott L Friedman, William R Sellers, Matthew Meyerson, Josep M Llovet
JournalCancer research (Cancer Res) Vol. 68 Issue 16 Pg. 6779-88 (Aug 15 2008) ISSN: 1538-7445 [Electronic] United States
PMID18701503 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
Topics
  • Adenocarcinoma (genetics, pathology)
  • Biomarkers, Tumor (genetics, metabolism)
  • Carcinoma, Hepatocellular (classification, genetics, virology)
  • Chromosome Aberrations
  • Chromosomes, Human, Pair 6 (genetics)
  • Chromosomes, Human, Pair 7 (genetics)
  • Gene Dosage
  • Gene Expression Profiling
  • Hepatitis B, Chronic (complications, genetics)
  • Hepatitis C, Chronic (complications, genetics)
  • Humans
  • Immunoenzyme Techniques
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Liver Neoplasms (classification, genetics, virology)
  • Lung Neoplasms (genetics, secondary)
  • Neoplasm Staging
  • Nucleic Acid Hybridization
  • Oligonucleotide Array Sequence Analysis
  • Prognosis
  • Signal Transduction
  • Survival Rate
  • Tissue Array Analysis
  • Vascular Endothelial Growth Factor A (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: